

AF 1000
1626
/

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of
David M. FINK, et al.

Examiner: **SHAMEEM, Golam M.**

Application No.: **10/088,250**

Art Unit: **1626**

Filed: **December 23, 2002**

Title: **THIENOSOXAZOLYL-AND
THIENYLPYRRAZOLYL PHENOXY
SUBSTITUTED PROPYL DERIVATIVES
USEFUL AS D4 ANTAGONISTS**

<p>Certificate of Mailing or Transmission I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop address below, or being facsimile transmitted to the USPTO, on the date indicated below. Date of Deposit <u>August 15, 2005</u> Printed Name of Person Signing Certificate <u>Brian Pritchett</u> Signature <u>Brian Pritchett</u></p>


**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
FOR WHICH THE FEE SPECIFIED UNDER 37 C.F.R. 1.97(c) IS REQUIRED**

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Enclosed is an Information Disclosure Statement for which the fee specified in 37 C.F.R. 1.97(c) is required.

Please charge Deposit Account No. **18-1982** in the amount of \$180.00. Two duplicate copies of this sheet are enclosed. The Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. **18-1982**.


Respectfully submitted,


Barbara E. Kurys, Reg. No. 34,650
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-2965
Telefax (908) 231-2626

Aventis Docket No. HMR2023 US PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re Application of

David M. FINK, et al.

Examiner: **SHAMEEM, Golam M.**

Art Unit: **1626**

Application No.: **10/088,250**

Filed: **December 23, 2002**

Title: **THIENOSOXAZOLYL-AND
THIENYLPYRRAZOLYL PHENOXY
SUBSTITUTED PROPYL
DERIVATIVES USEFUL AS D4
ANTAGONISTS**

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

August 15, 2005

Date of Deposit

Brian Pritchett
Signature

Brian Pritchett

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

- ☐ (a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. **18-1982**.

08/18/2005 EFL0RES 00000028 181982 10088250

01 FC:1806 180.00 DA

- ☒ (b) This Information Disclosure Statement is filed after the period set forth in 37 C.F.R. 1.97(b), but is believed to be filed before the mailing date of a final action under §1.113 or a notice of allowance under §1.311, whichever occurs first.
- ☐ (1) The undersigned attorney certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement;
- ☐ (2) The undersigned attorney certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned attorney after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement; or
- ☒ (3) This Information Disclosure Statement is accompanied by a transmittal letter in which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is authorized.


A concise explanation of the relevance of some or all of the items listed on the attached PTO-1449 (modified) is as follows:

The items listed with an asterisk on the attached PTO-1449 (modified) have been previously submitted by the examiner or the applicant in related applications of this series:
10/088,369

Therefore, a copy of the reference(s) are not enclosed with this Information Disclosure Statement.

Therefore, a copy of the reference(s) are not enclosed with this Information Disclosure Statement.

Respectfully submitted,


Barbara E. Kurys, Reg. No. 34,650
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-2965
Telefax (908) 231-2626
Aventis Docket No. HMR2023 US PCT

Please type a plus sign (+) inside this box → ☒

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

5

Complete if Known

Application Number	10/088,250
Filing Date	12-23-2002
First Named Inventor	FINK, et. al.
Group Art Unit	1626
Examiner Name	SHAMEEM, Golam M.
Attorney Docket Number	USHMR2023 - US - PCT

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	*	4,075,227		JONES, et. al.	02-21-1978	
	*	4,085,114		ADACHI, et. al.	04-18-1978	
	*	4,355,037		STRUPCZEWSKI, et. al.	10-19-1982	
	*	4,408,053		STRUPCZEWSKI, et. al.	10-04-1983	
	*	4,408,054		STRUPCZEWSKI, et. al.	10-04-1983	
	*	4,427,691		SHUTSKE, et. al.	01-24-1984	
	*	4,452,804		SHUTSKE, et. al.	06-06-1984	
	*	4,469,869		STRUPCZEWSKI, et. al.	09-04-1984	
	*	4,504,669		SHUTSKE, et. al.	03-12-1985	
	*	4,528,376		STRUPCZEWSKI, et. al.	07-09-1985	
	*	4,644,064		SHUTSKE, et. al.	02-17-1987	
	*	4,728,651		ONG, et. al.	03-01-1988	
	*	4,769,472		ONG, et. al.	09-06-1988	
	*	5,254,595		GUZZI, et. al.	10-19-1993	
	*	5,321,037		NAGANO, et. al.	06-14-1994	
	*	5,340,833		BRIDGES, et. al.	08-23-1994	
	*	5,593,994		BATT, et. al.	01-14-1997	
	*	5,696,113		PALERMO, et. al.	12-09-1997	
	*	5,843,940		CULLINAN, et. al.	12-01-1998	
	*	5,856,503		AEBI, et. al.	01-05-1999	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	*	EP	0058977		SHUTSKE, et. al.	09-01-1982		
	*	EP	0221414		ONG, et. al.	05-13-1987		
	*	EP	0729955		CULLINAN, et. al.	09-04-1996		
	*	WO	01/19833		FINK, et. al.	03-22-2001		
	*	WO	97/28115		ADAMS, et. al.	08-07-1997		
	*	GB	1,269,776		SMITH, et. al.	04-06-1972		

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

☒

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

(use as many sheets as necessary)

2

of

5

10/088,250

12-23-2002

FINK, et. al.

1626

SHAMEEM, Golam M.

USHMR2023 - US - PCT

[illegible][illegible]Date
Considered

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

Please type a plus sign (+) inside this box → ☒

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

3

of

5

Complete if Known

Application Number	10/088,250
Filing Date	12-23-2002
First Named Inventor	FINK, et. al.
Group Art Unit	1626
Examiner Name	SHAMEEM, Golam M.
Attorney Docket Number	USHMR2023 - US - PCT

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	*	ASGHARI, V., et. al., Dopamine D4 Receptor Repeat: Analysis of Different Native and Mutant Forms of the Human and Rat Genes, Molecular Pharmacology Vol. 46, pp. 364-373 (1994)	
	*	BASSITT, D.P., et. al., Clozapine Efficacy in Tardive Dyskinesia in Schizophrenic Patients; European Archives of Psychiatry and Clinical Neuroscience Vol.248, pp. 209-211 (1998)	
	*	BENJAMIN, J., et. al., Population and Familial Association between the D4 Dopamine Receptor gene and Measures of Novelty Seeking, Nature Genetics Vol. 12, pp. 81-84 (1996)	
	*	BRYCE, M., et. al., Synthesis and Cyclic Voltammetric Behaviour of Some 3-Substituted Thiophenes and Pyrroles: Precursors for the Preparation of Conducting Polymers, Synthetic Metal, Vol. 26, (1988) pp. 153- 168	
	*	CORBETT, R., et. al., Iloperidone: Preclinical Profile and Early Clinical Evaluation, CNS Drug Review Vol.3, No. 2, pp. 120 -147 (1997)	
	*	CRENSHAW, R.R., et. al., Potential Antifertility Agents, 1. Substituted Diaryl Derivatives of Benzo[b]thiophenes, Benzo[b]furans, 1H-2-Benzothiopyrans, and 2H-1-Benzothiopyrans, Journal of Medicinal Chemistry, Vol. 14, No.12, (1971) pp. 1185-1190	
	*	CRUZ, C., et. al., Increased Prevalence of the Seven-Repeat Variant of the Dopamine D4 Receptor Gene in Patients with Obsessive-Compulsive Disorder with Tics, Neuroscience Letters Vol. 231, pp. 1-4, (1997)	
	*	EBSTEIN, R.E., et. al., Dopamine D4 Receptor (D4DR) exon III Polymorphism Associated with the Human Personality Trait of Novelty Seeking, Nature Genetics Vol. 12, (1996) pp. 78-80	
	*	ELWORTHY, T. R., et. al., N-Arylpiperaziny-N-Propylamino Derivatives of Heteroaryl Amides as Functional Uroselective α 1-Adrenoceptor Antagonists, Indian Journal of Chemistry - part B Organic Including Medicinal Vol. 40, pp.2674-2687, (1997)	
	*	ERENBERG, G., et. al., Gilles De La Tourette's Syndrome: Effects of Stimulant Drugs, Neurology Vol.35, No. 35, pp.1346-1348, (1985)	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Release type a plus sign (+) inside this box → ☒

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

+

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 5

Complete if Known

Application Number	10/088,250
Filing Date	12-23-2002
First Named Inventor	FINK, et. al.
Group Art Unit	1626
Examiner Name	SHAMEEM, Golam M.
Attorney Docket Number	USHMR2023 - US - PCT

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	*	FACTOR, S.A., et. al., The Emerging Role of Clozapine in the Treatment of Movement Disorders, Movement Disorders Vol. 12, No.4 (1997) pp. 483-496	
	*	FELDPAUSCH, D.L., et. al., The Role of Dopamine D4 Receptor in the Induction of Behavioral Sensitization to Amphetamine and Accompanying Biochemical and Molecular Adaptations, Journal of Pharmacology and Experimental Therapeutics Vol. 266, pp.497-508 (1998)	
	*	FRIEDMAN, J.H., et. al., Substituting Clozapine for Olanzapine in Psychiatrically Stable Parkinson's Disease Patients: Results of an Open Label for Pilot Study, Clinical Neuropharmacology, Vol. 21, No. 5 pp. 285-288 (1998)	
	*	GRICE, D.E., et. al., Linkage Disequilibrium between an Allele at the Dopamine D4 Receptor Locus and Tourette Syndrome, by the Transmission-Disequilibrium Test, American Journal of Human Genetics Vol.59, pp.644-652 (1996)	
	*	HELSLEY, G.C., et. al., Piperidylalkylindoles. 1. Hypotensive Activity of 3-[2-(Phenoxypiperidyl)ethyl]Indoles, Journal of Medicinal Chemistry, (1978), Vol.21, No.3 pp. 309-312	
	*	LAHOSTE, G., et. al., Dopamine D4 Receptor Gene Polymorphism is Associated with Attention Deficit Hyperactivity Disorder, Molecular Psychiatry Vol. 1, pp. 121-124 (1996)	
	*	LAHTI, R.A., et. al., Direct Determination of Dopamine D4 Receptors in Normal and Schizophrenic Postmortem Brain Tissue: A [3H]NGD-94-1 Study, Molecular Psychiatry Vol. 3, pp. 528-533 (1998)	
	*	MAGDO, I., et. al., 3D quantitative structure-activity relationship (CoMFA) study of heterocyclic arylpiperazine derivatives with 5-HT1A activity, Database Chemabs 'Online! Chemical Abstracts Service, Columbus, Ohio, US	
	*	RICKETTS, H., et. al., Association of Long Variants of the Dopamine D4 Receptor Exon 3 Repeat Polymorphism with Parkinson's Disease, Clinical Genetics Vol. 54, pp. 33-38 (1998)	
	*	RUBINSTEIN, M., et. al., Mice Lacking Dopamine D4 Receptors are Supersensitive to Ethanol, Cocaine, and Methamphetamine, Cell, Vol.90, pp. 991-1001 (1997)	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box → ☒

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 5 of 5

Complete if Known

Application Number	10/088,250
Filing Date	12-23-2002
First Named Inventor	FINK, et. al.
Group Art Unit	1626
Examiner Name	SHAMEEM, Golam M.
Attorney Docket Number	USHMR2023 - US - PCT

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	*	SALL, D., et. al., Dibasic Benzo[b]thiophene Derivatives as a Novel Class of Active Site-Directed Thrombin Inhibitors. 1. Determination of the Serine Protease Selectivity, Structure - Activity Relationships, and Binding Orientation, Journal of Medicinal Chemistry Vol.40, No. 22, (1997) pp. 3489 - 3493	
	*	SCHODER, J., et. al., D2 Dopamine Receptor Up-Regulation, Treatment Response, Neurological Soft Signs, and Extrapyramidal Side Effects in Schizophrenia: A Follow-Up Study with 123I-Iodobenzamide Single Photon Emission Computed Tomography in the Drug Naive State and after Neuroleptic Treatment, Society of Biological Psychiatry Vol.43, pp.660-665, (1998)	
	*	SEEMAN, P., et. al., Atypical Neuroleptics Have Low Affinity for Dopamine D2 Receptors or Are Selectivefor D4 Receptors, Neuropsychopharmacology Vol.16, Iss. 2, pp. 92-135 (1997)	
	*	SEEMAN, P., et. al., Schizophrenia: Eleveation of dopamine D4-like sites, using [3H]Nemonapride and [125I]Epidepride , European Journal of Pharmacology Vol.286 (1995) R3-R5	
	*	SHIELDS, P.G., et. al., Dopamine D4 Receptors and the Risk of Cigarette Smoke in African-Americans and Caucasians ¹ , Cancer Epidemiology, Biomarkers & Prevention Vol. 7, pp.453-458 (1998)	
	*	VAN TOL, H.M., et. al., Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine, Letters to Nature, Vol. 350, 1991, pp 610-614	
	*	VAN TOL, H.M., et. al., The Dopamine D4 Receptor: A Novel Site for Antipsychotic Action , Clinical Neuropharmacology Vol. 18, No.1 pp. 5143-5153 (1995)	
	*	VANTOL, H.M., et. al., Mutiple Dopamine D4 Receptor Variants in the Human Population , Nature Vol. 358 - 9 (1992) - pp.149 -152	
	*	ZHU, J., et. al., Synthesis of 2-(4-Halogenobenzyl)-3-Arylbenzo[b]-Thiophenes and a 2-(4-Fluorobenzyl)-3-Arylbenzo[b]-Selenophene as Selective Ligands for Antiestrogen-Binding Sites	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

